Litcius/Paper detail

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

G. Falchook, B.T. Li, K.A. Marrone, C.M. Bestvina, C.J. Langer, J.C. Krauss, J.H. Strickler, A. Meloni, Tao Dai, T. Varrieur, D.S. Hong

2022Journal of Thoracic Oncology50 citationsDOIOpen Access PDF

Topics & Concepts

KRASMedicineCancer researchReceptor tyrosine kinaseAcquired resistanceKinaseProtein-Tyrosine KinasesTyrosine-kinase inhibitorTyrosine kinasePharmacologyReceptorInternal medicineCancerBiologyGeneticsColorectal cancerProtein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors | Litcius